RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model

Prostate

Volumn 68, Issue 8, 2008, Pages 820-829

  Woods Ignatoski, K M ^a   Escara Wilke, J F ^a   Dai, J L ^a   Lui, A ^a   Dougall, W ^c   Daignault, S ^b   Yao, Z ^d   Zhang, J ^e   Day, M L ^a,b   Sargent, E E ^a   Keller, E T ^a,b,f  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c AMGEN INC   (United States)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bone metastasis; Docetaxel; Prostate cancer; RANK Fc; RANKL

Indexed keywords

DOCETAXEL; IMMUNOGLOBULIN FC FRAGMENT; OSTEOCLAST DIFFERENTIATION FACTOR;

ADJUVANT THERAPY; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER MODEL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG INHIBITION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE AND BONES; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RANK LIGAND; RECOMBINANT FUSION PROTEINS; TAXOIDS;

EID: 45349086881     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20744     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun M. Cancer statistics, 2006. CA Cancer J Clin 2006;56(2):106-130.
2. Kreis W, Budman D, Fetten J, Gonzales A, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999;10(1): 33-38.
3. Williams J, Muenchen H, Kamradt J, Korenchuk S, Pienta K. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: An experimental study. Prostate 2000;44(4):275-278.
4. Pienta K. Precuneal mechanisms of action of docetaxeland docetaxel combinations in prostate cancer. Semin Oncol 2001;28: 3-7.
5. Ramaswamy B, Puhalla S. Docetaxel: Tubulin-stabilizing agent approved for management of solid tumors. Drugs Today (Barc) 2006;42(4):265-279.
6. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 1999;26 (5 Suppl 17):14-18.
7. Pienta K. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001;28 (4 Suppl 15):3-7.
8. Britain BMAatRPSoG. British national formulary, 50th edition. London: Pharmaceutical Press; 2005.
9. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: A new era begins. CA Cancer J Clin 2006;55:300-318.
10. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc) 2002;38:91-102.
11. Keller E, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91(4): 718-729.
12. Thomas R, Guise T, Yin J, Elliott J, Horwood N, Martin T, MT G. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140(10):4451-4458.
13. Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004;4(3):308-318.
14. Guise T, Mohammad K, Clines G, Stebbins E, Wong D, Higgins L, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin J. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12 (20 Pt 2):6213s-6216s.
15. Brown J, Zhang J, ET K. Opg, RANK1, and RANK in cancer metastasis: Expression and regulation. Cancer Treat Res 2004; 118:149-172.
16. Zhang J, Dai J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller E. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107(10):1235-1244.
17. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller E. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 2003;63(22):7883-7890.
18. Vessella R, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006;12 (20 Pt 2):6285s-6290s.
19. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 1994; 57(3):406-412.
20. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54(10):2577-2581.
21. Davol P, Frackelton AJ. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: Characterizing and circumventing mechanisms of tumor resistance. Prostate 1999;40(3):178-191.
22. Porter A, McEwan A, Powe J, Reid R, McGowan D, Lukka H, Sathyanarayana J, Yakemchuk V, Thomas G, Erlich L, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25(5):805-813.
23. Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin J, Vinholes J, Goas J, Zheng M. Group ZAPCS. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. JNCI 2004;96(11):879-882.
24. Winquist E, Berry S. A randomized placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. JNCI 2004;96:1183-1184.
25. Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006; 6:15.
26. Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis 2005;8:253-259.
27. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65(17):7554-7560.
28. Hall C, Kang S, MacDougald O, Keller E. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 2006;97(4):661-672.
29. Hall C, Keller E. The role of Wnts in bone metastases. Cancer Metastasis Rev 2006;25(4):551-558.
30. Corey E, Quinn J, Bladou F, Brown L, Roudier M, Brown J, Buhler K, Vessella R. Establishment and characterization of osseous prostate cancer models: Intia-tibial injection of human prostate cancer cells. Prostate 2002;52(1):20-33.
31. Schneider A, Kalikin L, Mattos A, Keller E, Allen M, Pienta K, McCauley L. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005;146(4):1727-1736.
32. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niaz iZ, Strafte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163(1):181-186.
33. Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 2001;86(2): 511-516.
34. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007;177(1):17-24.
35. Bucay N, Sarosi I, Dunstan C, Morony S, Tarpley J, Capparelli C, Scully S, Tan H, Xu W, Lacey D, Boyle W, Simonet W. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12(9):1260-1268.
36. Takahashi N, Ozawa H. A new treatment for osteoporosis using fully human monoclonal antibody to RANKL, AMG 162. Clin Calcium 2005;15(1):43-48.
37. Saad F. Zoledronic acid: Past, present and future roles in cancer treatment. Future Oncol 2005;1(2):149-159.
38. Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol 2006;24(1):4-12.
39. Vessella R, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006;12 (20 Pt 2):6285s-6290s.
40. Lewiecki E. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006;6(10): 1041-1050.
41. Kim S, Uehara H, Yazici S, He J, Langley R, Mathew P, Fan D, Fidler I. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005;65(9):3707-3715.
42. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115-1117.
43. Mortensen M, Lawson W, Montazem A. Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review. Laryngoscope 2007;117(1):30-34.
44. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62(6):1619- 1623.
45. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 2004;59(3):304-310.
46. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 2005;65(5):1710-1718.